<unk> , sold under the brand name Regkirona, is a human monoclonal antibody used for the treatment of COVID-19. The antibody is directed against the spike protein of SARS-CoV-2. It is developed by Celltrion. The medicine is given by infusion (drip) into a vein. The most common side effects include infusion-related reactions, including allergic reactions and anaphylaxis.<unk>  was approved for medical use in the European Union in November 2021.
Regdanvimab
Atoltivimab
Odesivimab
Nirsevimab
Obiltoxaximab
Sotrovimab
Lirentelimab
Ansuvimab